Manufacturer
Pfizer
Contents
Olmesartan medoxomil/amlodipine besylate
Indication
Essential HTN in patient whose BP is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Instruction
May be taken with or without food.
Drug Interaction
Increased BP lowering effect by other antihypertensive agents. Increased serum K w/ K-sparing diuretics, K supplements, salt substitutes containing K or heparin, ACE inhibitors. Increased serum lithium conc & toxicity. Increased risks of hypotension, hyperkalemia & changes in renal function w/ angiotensin-receptor blockers, ACE inhibitors or aliskiren. Caution w/ NSAIDs including selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) & nonselective NSAIDs. Reduction in olmesartan bioavailability w/ Al Mg hydroxide antacids. Increased amlodipine plasma conc w/ CYP3A4 inhibitors. Lowered amlodipine plasma conc w/ CYP3A4 inducers.
Malaysia
